homepage-banner.jpg
Mereo-Biopharma---logo.png

Unlocking healthcare potential for patients

Leveraging our expertise to address unmet medical needs

Our Strategy

Mereo BioPharma is an innovative leader in the biopharma sector with a focus on developing and optimizing the value of novel medicines acquired from large pharmaceutical companies designed to address significant unmet medical needs in rare and specialty disease areas.

Mereo BioPharma plans to build a rare and orphan disease commercial business based on products acquired from major pharmaceutical companies.

Find out more about our strategy

our products

Mereo has built an initial mid-late stage portfolio of four exceptionally well characterised novel products, three from Novartis and one from AstraZeneca, for the treatment of diseases with considerable unmet medical need.

Each of these programmes has a comprehensive dataset for both pre-clinical and initial phase 2 clinical studies.

 

BPS-804 MPH-966 BGS-649 BCT-197

Investors

Share Price

View Share Price Chart

Events and conferences

  • 18 May 2018 AETHER Phase 2 clinical trial data to be presented at the American Thoracic Society meeting in San Diego, 18 to 23 May
  • 26 Sep 2017 Mereo BioPharma to present at the Cantor Global Healthcare Conference in New York, 25-27 September 2017
  • 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
View All Events